AIM ImmunoTech Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $7.3M
- Price
- $0.182
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.44%
- Volume
- 242.8K
About
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
Quick stats
Shares outstanding39.9M
Computed float27.3M
Float / shares68.4%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000946644
Websitehttps://aimimmuno.com
AI Summary
AI-generated1/50
minorneutralother
AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays
AIM ImmunoTech spotlighted a BioTuesdays feature on its strategy to use Ampligen as a maintenance therapy in metastatic pancreatic cancer following first-line chemotherapy.
Final dosing is complete in the Phase 2 DURIPANC trial pairing Ampligen with AstraZeneca's Imfinzi, with primary and secondary endpoints still pending.
The feature also cites exploratory Named Patient Program data: in 39 Dutch patients with an NLR below 4.5, median overall survival was 34.8 months from FOLFIRINOX start, though these uncontrolled observations do not establish efficacy.
Red flags
- NPP survival figures are exploratory, uncontrolled, and explicitly not efficacy evidence
- Company may need financing or a pharma partnership to fund a pivotal Phase 3 study